Type I interferons as mediators of immune adjuvants for T- and B cell-dependent acquired immunity.
Originally identified as antiviral substances produced by infected cells, type I interferons (IFN-I) are now known to have a wide range of additional activities within both the innate and adaptive immune response. Here we review properties of IFN-I contributing to their 'natural immune adjuvant' character, and their important role for the function of complete Freund's adjuvant (CFA) and the TLR9-dependent immune adjuvant IC31. We show data to demonstrate that treatment with IFN-I boosts the ability of vaccine/adjuvant combinations to induce peptide-specific CTL in both young and old mice. We view these findings in the perspective of previous clinical applications of IFN-I for vaccination.
Prchal
Michaela
M
Department of Pharmacology, Medical University of Vienna, Austria; Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, Austria.
Pilz
Andreas
A
Simma
Olivia
O
Lingnau
Karen
K
von Gabain
Alexander
A
Strobl
Birgit
B
Müller
Mathias
M
Decker
Thomas
T
D056704:Adaptive Immunity; D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology; D003602:Cytotoxicity, Immunologic; D004338:Drug Combinations; D005620:Freund's Adjuvant / Q000276:immunology; D007370:Interferon Type I / Q000276:immunology*; D051379:Mice; D009838:Oligodeoxyribonucleotides; D009842:Oligopeptides; D013601:T-Lymphocytes / Q000276:immunology*; D014612:Vaccines / Q000276:immunology
D000276:Adjuvants, Immunologic; D004338:Drug Combinations; C544002:IC31 adjuvant; D007370:Interferon Type I; D009838:Oligodeoxyribonucleotides; D009842:Oligopeptides; D014612:Vaccines; D005620:Freund's Adjuvant